Guo, Sijin https://orcid.org/0000-0003-0075-2299
Vieweger, Mario https://orcid.org/0000-0002-0510-9633
Zhang, Kaiming https://orcid.org/0000-0003-0414-4776
Yin, Hongran https://orcid.org/0000-0001-5417-2754
Wang, Hongzhi https://orcid.org/0000-0002-4383-9784
Li, Xin https://orcid.org/0000-0001-5085-5734
Li, Shanshan https://orcid.org/0000-0002-7041-5960
Hu, Shuiying https://orcid.org/0000-0002-9806-7734
Sparreboom, Alex https://orcid.org/0000-0003-2660-6644
Evers, B. Mark https://orcid.org/0000-0002-9425-2342
Dong, Yizhou https://orcid.org/0000-0001-5786-0659
Chiu, Wah https://orcid.org/0000-0002-8910-3078
Guo, Peixuan https://orcid.org/0000-0001-5706-2833
Funding for this research was provided by:
Foundation for the National Institutes of Health (R01CA195573)
Foundation for the National Institutes of Health (U01CA207946)
Foundation for the National Institutes of Health (R01EB019036)
Foundation for the National Institutes of Health (R01CA195573)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (S10OD021600)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (P41GM103832)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences
Article History
Received: 27 March 2019
Accepted: 24 January 2020
First Online: 20 February 2020
Competing interests
: P.G. is the consultant of Oxford Nanopore Technologies, the co-founder of Shenzhen P&Z Bio-medical Co. Ltd, and the co-founder of the ExonanoRNA, LLC and its subsidiary ExonanoRNA (Foshan) Biomedicine Co., Ltd.